Pre-made Idactamab benchmark antibody ( Whole mAb, anti-SLC1A5 therapeutic antibody, Anti-AAAT/ASCT2/ATBO/M7V1/M7VS1/R16/RDRC Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Idactamab biosimilar, Whole mAb, Anti-SLC1A5 Antibody: Anti-AAAT/ASCT2/ATBO/M7V1/M7VS1/R16/RDRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Idactamab biosimilar, Whole mAb, Anti-SLC1A5 Antibody: Anti-AAAT/ASCT2/ATBO/M7V1/M7VS1/R16/RDRC therapeutic antibody |
|---|---|
| INN Name | Idactamab |
| Target | SLC1A5 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | MedImmune |
| Conditions Approved | NA |
| Conditions Active | Acute myeloid leukemia,Multiple myeloma,Diffuse large B-cell lymphoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SLC1A5 |
| Package |
